Groups | Type of cancer | Parameter | PtSupp(mg) | Pt (μg) | Se (μg) | As (ng) |
---|---|---|---|---|---|---|
Cisplatin (Group 1) | Lung | X | 163.0 | 35.3 | 3.62 | 127.0 |
Med | 156.0 | 28.2 | 1.28 | 23.5 | ||
DS | 66.6 | 25.9 | 6.45 | 267.0 | ||
n | 32 | 32 | 24 | 21 | ||
Min | 39.1 | 3.94 | 0.208 | 1.88 | ||
Max | 263.0 | 90.4 | 22.0 | 1180.0 | ||
Cisplatin (Group 2) | Other | X | 174.0 | 40.1 | 1.35 | 216.0 |
Med | 120.0 | 32.5 | 1.22 | 71.0 | ||
DS | 324.0 | 36.1 | 0.717 | 424.0 | ||
n | 47 | 47 | 36 | 31 | ||
Min | 31.6 | 0.760 | 0.354 | 18.8 | ||
Max | 2297.0 | 175.0 | 2.84 | 2300.0 | ||
Carboplatin (Group 3) | Other | X | 695.0 | 262.0 | 1.59 | 40.8 |
Med | a | a | a | a | ||
DS | 189.0 | 201.0 | 0.711 | 46.9 | ||
n | 11 | 11 | 9 | 6 | ||
Min | 433.0 | 9.80 | 0.516 | 2.53 | ||
Max | 917.0 | 680.0 | 2.52 | 121.0 | ||
Control 1 (b) (Group 4) | Other | X | 1.77 | 62.0 | ||
Med | a | a | ||||
DS | 1.14 | 59.4 | ||||
n | 7 | 2 | ||||
Min | 0.333 | 20.0 | ||||
Max | 3.29 | 104.0 | ||||
Control 2 (c) (Group 5) | Lung and other | X | 1.47 | 48.2 | ||
Med | a | a | ||||
DS | 0.58 | 1.56 | ||||
n | 9 | 2 | ||||
Min | 0.45 | 47.1 | ||||
Max | 2.16 | 49.3 |